ORN Fall 2023 - Brixadi (buprenorphine-XR) for the Treatment of Opioid Use Disorder-Recording 2023-09-13

Video Transcription

Video Summary

Summary: This webinar focused on Brixadi, an extended-release formulation of buprenorphine for the treatment of opioid use disorder. Dr. Antoine Deweyhe provided an overview of the drug and its benefits, including reduced medication burden and improved retention in treatment. He also discussed ongoing trials, such as the MOM study that evaluates Brixadi in pregnant women, and the CTN-100 study that examines strategies for optimizing retention and discontinuation. Dr. Deweyhe highlighted the flexibility in dosing and administration, as well as the potential challenges in converting patients from sublingual buprenorphine to Brixadi. Overall, the webinar aimed to provide insights into the efficacy and clinical implications of Brixadi, and to address common questions and concerns surrounding its use.

Keywords

Brixadi

extended-release formulation

buprenorphine

opioid use disorder

medication burden

improved retention

MOM study

pregnant women

CTN-100 study

dosing and administration